Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 Recruiting
83 enrolled
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Phase 2 Recruiting
42 enrolled
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Phase 2 Recruiting
164 enrolled
iPRRT
Phase 2 Recruiting
18 enrolled
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2 Recruiting
30 enrolled
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 Recruiting
120 enrolled
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Phase 2 Recruiting
100 enrolled
ANALLISA
Phase 2 Recruiting
30 enrolled
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Phase 2 Recruiting
36 enrolled
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 Recruiting
52 enrolled
MYELO-CAN:TXA
Phase 2 Recruiting
75 enrolled
TIGOS-LS
Phase 2 Recruiting
250 enrolled
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Phase 2 Recruiting
22 enrolled
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
Phase 2 Recruiting
62 enrolled
PrE0510
Phase 2 Recruiting
60 enrolled
PREDICT-RD
Phase 2 Recruiting
78 enrolled
I-MAMMO
Phase 2 Recruiting
364 enrolled
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
Phase 2 Recruiting
49 enrolled
APSOC
Phase 2 Recruiting
73 enrolled
Pinoxin for the Prevention of Radiation-Induced Skin Injury
Phase 2 Recruiting
202 enrolled
NIBCUN
Phase 2 Recruiting
36 enrolled
IVIG for Infection Prevention After CAR-T-Cell Therapy
Phase 2 Recruiting
150 enrolled
MOAB
Phase 2 Recruiting
80 enrolled
NUMER
Phase 2 Recruiting
120 enrolled
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Phase 2 Recruiting
112 enrolled
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Phase 2 Recruiting
164 enrolled
MOMENTUM-1
Phase 2 Recruiting
153 enrolled
EZHiSWITCH
Phase 2 Recruiting
900 enrolled
FACT-TN
Phase 2 Recruiting
80 enrolled
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Phase 2 Recruiting
25 enrolled
PEMIGIST
Phase 2 Recruiting
24 enrolled
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Phase 2 Recruiting
104 enrolled
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Phase 2 Recruiting
30 enrolled
Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 Recruiting
35 enrolled
HYPNOMUSE
Phase 2 Recruiting
45 enrolled
Study of Lacutamab in Peripheral T-cell Lymphoma
Phase 2 Recruiting
56 enrolled
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Phase 2 Recruiting
35 enrolled
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Phase 2 Recruiting
20 enrolled
NePenThe
Phase 2 Recruiting
25 enrolled
CAR T-cell Therapy in Patients With Renal Dysfunction
Phase 2 Recruiting
20 enrolled
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 Recruiting
220 enrolled
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Recruiting
30 enrolled
DIVINE
Phase 2 Recruiting
532 enrolled
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
Phase 2 Recruiting
16 enrolled
SAFE ESO
Phase 2 Recruiting
95 enrolled
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Phase 2 Recruiting
60 enrolled
TROY
Phase 2 Recruiting
116 enrolled
EEEA-AMSBP
Phase 2 Recruiting
126 enrolled
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
Phase 2 Recruiting
145 enrolled